Several panel members stressed that the five-axis format will allow a diverse list of useful information.
"We don’t want to be constrained by the approved indications," Dr. Nutt said. "This is an opportunity to document off-label indications and to link to the evidence for off-label uses," said Dr. Guy Goodwin, chairman of psychiatry at the University of Oxford (England) and another collaborator on the panel.
The audience of about 150 congress attendees at the session seemed persuaded by the speakers. At the session’s end, in an electronic vote, 67% said they fully agreed, and another 26% said they partly agreed, that the existing nomenclature needs revision. Asked whether the proposed nomenclature was a step in the right direction, 48% said they fully agreed, and another 39% said they partly agreed. Another question asked what feature should drive a drug’s top-line definition. Sixty percent of the audience said pharmacologic action, and an additional 29% voted in favor of clinical indication.
Dr. Zohar said he has been an adviser or consultant to or received research support from eight drug companies. Dr. Nutt said he has been an adviser or consultant to eight drug companies. Dr. Stahl said he has been an adviser or consultant to more than 30 drug companies. Dr. Goodwin said he had been an adviser or consultant to 12 drug companies.
On Twitter @mitchelzoler